Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Ventyx Biosciences announced upcoming presentations at major investor conferences. CEO Raju Mohan will provide an overview at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 10:30 AM ET, and participate in the 33rd Annual Piper Sandler Healthcare Conference with an on-demand fireside chat starting November 22, 2021. The company focuses on developing therapies for inflammatory diseases and has several clinical candidates, including VTX958 and VTX002. Webcasts will be available on the company’s website following each event.

ENCINITAS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview at the following upcoming investor conferences:

• Event: 4^th Annual Evercore ISI HealthCONx Conference
  Location: Virtual
  Date: Wednesday, December 1, 2021
  Time: 10:30-10:50 AM ET

• Event: 33^rd Annual Piper Sandler Healthcare Conference
  Location: Virtual
  Fireside Chat: A pre-recorded fireside chat will be available on-demand beginning on Monday, November 22nd at 10:00am ET

Members of the Ventyx management team will also host investor meetings during both conferences.

Webcasts of both presentations will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of each event for 30 days.

About Ventyx

Ventyx is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Our clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit www.ventyxbio.com.

Contacts:

Investor Relations Contact:
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com

FAQ

What is Ventyx Biosciences' upcoming conference schedule for December 2021?

Ventyx Biosciences will present at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 10:30 AM ET.

When will Ventyx's fireside chat be available for the Piper Sandler Healthcare Conference?

The pre-recorded fireside chat for the Piper Sandler Healthcare Conference will be available on-demand starting November 22, 2021, at 10:00 AM ET.

What therapies is Ventyx Biosciences developing for inflammatory diseases?

Ventyx is developing several therapies, including VTX958, a Phase 1 TYK2 inhibitor, and VTX002, a Phase 2-ready S1P1 receptor modulator.

Where can I find webcasts of Ventyx's conference presentations?

Webcasts of Ventyx's presentations will be available in the Investors and News section on their website shortly after each event.

What is the focus of Ventyx Biosciences as a biopharmaceutical company?

Ventyx focuses on advancing new therapies for patients with inflammatory diseases and autoimmune disorders.